Patents by Inventor Gene Merutka
Gene Merutka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11878047Abstract: Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.Type: GrantFiled: January 3, 2019Date of Patent: January 23, 2024Assignee: Sapience Therapeutics, Inc.Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo
-
Publication number: 20230218717Abstract: Provided are methods of administering a peptide antagonist of CCAAT/enhancer-binding protein beta (C/EBP?) and methods of treating solid tumors by administering a peptide antagonist of C/EBP?.Type: ApplicationFiled: June 21, 2021Publication date: July 13, 2023Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo, Alice Susannah Bexon, Robert E. Michel
-
Publication number: 20220275036Abstract: Provided are BCL9 mimetic peptides having a modified a-helical homology domain-2 (HD2) region and, optionally, a cell-penetrating region, compositions comprising the BCL9 mimetic peptides, and methods of inhibiting proliferation of and/or promoting cytotoxicity in a neoplastic cell using the BCL9 mimetic peptides.Type: ApplicationFiled: July 6, 2020Publication date: September 1, 2022Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo, Erin E. Gallagher
-
Publication number: 20210061869Abstract: Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.Type: ApplicationFiled: January 3, 2019Publication date: March 4, 2021Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo
-
Patent number: 10525100Abstract: Provided are activating transcription factor 5 (ATF5) peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.Type: GrantFiled: January 3, 2019Date of Patent: January 7, 2020Assignee: Sapience Therapeutics, Inc.Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo
-
Publication number: 20190201483Abstract: Provided are ATF5 peptides having a truncated ATF5 leucine zipper region and, optionally, a cell-penetrating region, compositions comprising the ATF5 peptides, and methods of inhibiting proliferation of and promoting cytotoxicity in a neoplastic cell using the ATF5 peptides.Type: ApplicationFiled: January 3, 2019Publication date: July 4, 2019Inventors: Barry Jay Kappel, Gene Merutka, Jimmy Andrew Rotolo
-
Patent number: 10316077Abstract: Provided are cell-penetrating ATF5 polypeptides having a cell-penetrating region and an ATF5 leucine zipper region, compositions comprising the ATF5 polypeptides, and methods of treating a tumor and promoting cytotoxicity in a neoplastic cell using the ATF5 polypeptides.Type: GrantFiled: February 17, 2018Date of Patent: June 11, 2019Assignee: Sapience Therapeutics, Inc.Inventors: Barry Jay Kappel, Jimmy Andrew Rotolo, Gene Merutka
-
Publication number: 20180237499Abstract: Provided are cell-penetrating ATF5 polypeptides having a cell-penetrating region and an ATF5 leucine zipper region, compositions comprising the ATF5 polypeptides, and methods of treating a tumor and promoting cytotoxicity in a neoplastic cell using the ATF5 polypeptides.Type: ApplicationFiled: February 17, 2018Publication date: August 23, 2018Inventors: Barry Jay Kappel, Jimmy Andrew Rotolo, Gene Merutka
-
Publication number: 20090326193Abstract: The present invention relates to alkylglycoside-containing compositions and methods for preventing loss of a parathyroid hormone (PTH) analog or octreotide via denaturation due to adherence upon contact with glass.Type: ApplicationFiled: June 25, 2009Publication date: December 31, 2009Applicants: Aegis Therapeutics LLC, Zelos TherapeuticsInventors: Edward T. Maggio, Gene Merutka
-
Patent number: 7297784Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.Type: GrantFiled: January 24, 2003Date of Patent: November 20, 2007Assignee: Trimeris, Inc.Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
-
Patent number: 6750008Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.Type: GrantFiled: July 9, 1999Date of Patent: June 15, 2004Assignee: Trimeris, Inc.Inventors: Peter Jeffs, John William Lackey, Joel Burton Erickson, Mary Katherine Lawless, Gene Merutka
-
Patent number: 6656906Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.Type: GrantFiled: July 9, 1999Date of Patent: December 2, 2003Assignee: Trimeris, Inc.Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
-
Publication number: 20030186874Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.Type: ApplicationFiled: January 24, 2003Publication date: October 2, 2003Applicant: Trimeris, Inc.Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
-
Patent number: 6562787Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.Type: GrantFiled: April 13, 2001Date of Patent: May 13, 2003Assignee: Trimeris, Inc.Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
-
Patent number: 6348568Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.Type: GrantFiled: May 20, 1999Date of Patent: February 19, 2002Assignee: Trimeris, Inc.Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
-
Patent number: 6258782Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.Type: GrantFiled: May 20, 1998Date of Patent: July 10, 2001Assignee: Trimeris, Inc.Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
-
Patent number: 6015881Abstract: The present invention relates, first, to methods for the synthesis of peptides, in particular T-20 (also referred to as "DP-178"; SEQ ID NO:1) and T-20-like peptides. Such methods utilize solid and liquid phase synthesis procedures to synthesize and combine groups of specific peptide fragments to yield the peptide of interest. The present invention further relates to individual peptide fragments which act as intermediates in the synthesis of the peptides of interest (e.g., T-20). The present invention still further relates to groups of such peptide intermediate fragments which can be utilized together to produce full length T-20 and T-20-like peptides.Type: GrantFiled: May 1, 1998Date of Patent: January 18, 2000Assignee: Trimeris, Inc.Inventors: Myung-Chol Kang, Brian Bray, Maynard Lichty, Catherine Mader, Gene Merutka